Hinova Pharmaceuticals, Inc. Class A

As of June 30, 2026, Hinova Pharmaceuticals, Inc. Class A carries a market capitalization of 3.48B, placing it among publicly traded companies globally. Its enterprise value stands at 2.80B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Hinova Pharmaceuticals, Inc. Class A has 99.02M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 53.44, and the price-to-book ratio stands at 3.46.

These figures are as of June 30, 2026. The EV/Sales ratio of 42.95 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.80B versus a market cap of 3.48B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Hinova Pharmaceuticals, Inc. Class A maintains a current ratio of 6.17, meaning it holds 6.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 10.40, indicating elevated leverage, while an interest coverage ratio of -628.12 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Hinova Pharmaceuticals, Inc. Class A posted a negative return on equity (ROE) of -11.43, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -9.61, reflecting losses generated across the asset base. The company generates approximately 290,995.55 in revenue per employee across its workforce of 224.25, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Hinova Pharmaceuticals, Inc. Class A recorded 3,095.13 in income tax expense. The company reported a pretax loss of -124.07M and -124.08M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Hinova Pharmaceuticals, Inc. Class A's stock has declined approximately 46.13% over the past 52 weeks. The 50-day moving average sits at 32.81, while the 200-day moving average is 39.98.

Over the twelve months ended June 30, 2026, Hinova Pharmaceuticals, Inc. Class A generated 65.26M in revenue and converted that into -124.08M in net income, yielding earnings per share of -1.25. EBITDA reached -122.07M, while operating income came in at -138.17M.

As of June 30, 2026, Hinova Pharmaceuticals, Inc. Class A holds 784.73M in cash and equivalents against 104.76M in total debt, resulting in a net debt position of -213.70M. Total book value stands at 1.01B, with working capital of 717.56M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The operating margin of -211.74 and net profit margin of -190.14 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Hinova Pharmaceuticals, Inc. Class A paid dividends of 0.02 per share. The dividend payout ratio of -1.57 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -2.72, meaning Hinova Pharmaceuticals, Inc. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Hinova Pharmaceuticals, Inc. Class A has an Altman Z-Score of 6.35, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.